Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Gilead’s remdesivir faces pricing and generic challenges, says GlobalData

There are concerns over the pricing of remdesivir and how to make it available in low-income and lower-middle income countries, says GlobalData, a leading data and analytics company. Historically, intravenously (IV) administered drugs come with a large price tag, but pharmaceutical companies are facing pressure to forego profits in exchange for reputation gains and goodwill. […]
Read more

Telemedicine expected to be used at high levels after the COVID-19 crisis, with most potential in chronic disease management, says GlobalData

A total *76% of people, as surveyed by GlobalData, expect telemedicine to be used widely once the pandemic had abated. Kathryn Whitney, MSc, Director of Thematic Analysis, comments: “Telemedicine offers patients better access to care, improved health outcomes and increased patient empowerment. For healthcare professionals, it allows high-risk patients to be monitored and treated more […]
Read more

COVID-19 to boost healthcare wearables uptake, but consumer protection concerns remain, says GlobalData

The health and fitness wearables that monitor physiological parameters such as heart rate, body temperature, sleeping patterns, blood pressure and oxygen saturation levels may become an effective early-warning system to detect COVID-19 if regulatory, safety and consumer protection requirements are addressed, says GlobalData, a leading data and analytics company. Urte Jakimaviciute MSc, Senior Director of […]
Read more

Dexamethasone and remdesivir could compliment each other, says GlobalData

After receiving a world-first approval by the UK Government, following groundbreaking data showing it can reduce COVID-19 deaths among hospitalized patients, the inexpensive and widely available corticosteroid dexamethasone has been getting significant attention. While data supporting dexamethasone’s efficacy seem clear, the magnitude of its benefit remains modest. Further, additional studies are warranted so as to […]
Read more

IVIg is available for treating COVID-19

While researchers investigate recovered patient antibody treatments for COVID-19, intravenous immunoglobulin (IVIg) is a similar type of treatment that is already available and could be used for COVID-19, says GlobalData, a leading data and analytics company. Johanna Swanson, Product Manager at GlobalData, comments: “IVIg is generated from the pooled immunoglobulin G of approximately one thousand blood […]
Read more

Less than 30% of AML cases considered to be in adverse risk group

Acute myeloid leukemia (AML), a serious haematological cancer, remains a disease often defined by poor prognosis. However, less than 30% of diagnosed incident cases of AML are considered of adverse risk, according to GlobalData, a leading data analytics company. The company’s latest report, ‘Acute Myeloid Leukemia: Epidemiology Forecast to 2029’, reveals that by 2029, there […]
Read more

Gilead’s inhaled remdesivir to commence Phase I trials, but new formulation may be required, says GlobalData

Following Gilead’s announcement that it will begin Phase I clinical trials for inhaled remdesivir in healthy volunteers, data and analytics company GlobalData anticipates that a new route of administration will specifically target patients with mild to moderate COVID-19 infection and will be administered via a nebuliser so that patients can  self-administer away from hospital. GlobalData […]
Read more

Despite temporary increased drug sales for most big bio/pharma companies, Regeneron Pharmaceuticals falls short of Q1 2020 forecast, says GlobalData

Despite the COVID-19 challenges, most of the big bio/pharma companies had reported temporary increase in drug sales in Q1 2020, mainly due to the stockpiling in preparation for reduced or no medical access during the lockdown. However, not all companies fared equally. Regeneron Pharmaceuticals was the only company to fall short of its Q1 2020 […]
Read more

Generic remdesivir approval will limit COVID-19 death rate in India post lockdown exit, says GlobalData

Following the news that domestic pharma giants Cipla and Hetero have received the Drugs Controller General of India’s (DGCI) approval to launch generic versions of remdesivir for COVID-19 treatment under the brand names Cipremi and Covifor respectively; Ms. Sasmitha Sahu, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “The approval […]
Read more

Dexamethasone could be another potential opportunity for Indian pharma companies, says GlobalData

Following the news that Indian drug firms cheer dexamethasone’s efficacy in severe COVID-19 patients;Nag Madhavi, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “Dexamethasone, an anti-inflammatory corticosteroid, is used for the treatment of various diseases such as inflammatory diseases, certain autoimmune diseases, skin conditions, asthma, lung conditions, and allergic reactions. […]
Read more

BeiGene’s commercialization experience will help it devise effective launch strategy for Brukinsa, says GlobalData

BeiGene has recently received approval for its second-generation Bruton’s tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib) from the China National Medical Products Administration (NMPA). The China-based biotech firm’s experience of commercializing partner Celgene’s (now Bristol Myers Squibb) drugs will help in devising effective launch strategy for Brukinsa, says GlobalData, a leading data analytics and research company. […]
Read more
1 … 88 89 90 91 92 … 110